Heidi Overton’s nomination to lead the Food and Drug Administration is withdrawn just before a Senate committee vote

Heidi Overton’s nomination to lead the Food and Drug Administration is withdrawn just before a Senate committee vote

The White House has withdrawn Heidi Overton’s nomination to lead the Food and Drug Administration, a White House official said, just one day before a Senate committee was set to vote on it.

President Donald Trump announced Overton as his choice in August, calling the physician and White House adviser a “ROCKSTAR.” She was nominated to replace Marty Makary, who resigned in May.

At her confirmation hearing in September, Overton faced questions from Sen. Bernie Sanders, I-Vt., who urged her to support universal health care as a human right.

Senate Health Committee Chairman Bill Cassidy, R-La., questioned Overton about her appearance with Trump in the Oval Office as he signed an order seeking changes to childhood vaccine recommendations, including separating the measles, mumps and rubella vaccine into individual shots.

Cassidy said there was no scientific evidence to support Trump’s suggestion that the combined vaccine could be “quite lethal,” and warned that the comment could discourage people from getting vaccinated.

“Yes, Senator, the MMR vaccine is safe and effective,” Overton told Cassidy. Asked what she would do if Trump told her to set aside the FDA’s safety standards, she said she would offer the president her best advice and follow legal requirements when reviewing individual products.

Sen. Maggie Hassan, D-N.H., asked whether Trump was wrong. Overton again said the vaccine was safe and effective, describing it as the best tool available during the measles outbreak. Sen. Ed Markey, D-Mass., asked why she had not corrected Trump in the Oval Office.

“So why should we expect you to stand up to the president as FDA commissioner?” Markey asked.

As a White House adviser, Overton worked on several of the administration’s Make America Healthy Again initiatives. Before returning to the White House, she was vice chair and chief policy officer at the conservative America First Policy Institute. In a 2023 policy brief, she criticized expanded access to abortion pills.

Kyle Diamantas has served as acting head of the FDA since Makary’s departure.

Erik Baptist, senior vice president for legal strategy at SBA Pro-Life America, said the group wants the next FDA nominee to commit to ending mail-order access to abortion drugs and changing how the agency studies their safety before a Senate confirmation vote.

“The administration must immediately end the Biden FDA’s mail-order abortion-drug scheme and protect pregnant women from predators who coerce or poison women with these drugs,” Baptist said. “And the FDA must fix its flawed safety study by obtaining robust data, increasing real-time transparency, and inviting external experts to help with this study.”

“Confirmation is not a coronation,” he added. “It is a time to vet nominees and seek commitments before they take office.”

Facebook
Twitter
LinkedIn
Reddit
Telegram
WhatsApp

Related News